Livtencity
What Livtencity is used for
LIVTENCITY is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT). Consideration should be given to official guidance on the appropriate use of antiviral agents.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Livtencity
- Active substance
- maribavir
- Disease area
- Cytomegalovirus Infections
- Medicine group
- Antivirals for systemic use
- ATC code
- J05AX10
- Marketing authorisation holder
- Takeda Pharmaceuticals International AG Ireland Branch
- Authorised in the EU since
- 2022
Official information
In the USA
Same active substance: Livtencity
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Livtencity used for?
LIVTENCITY is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT). Consideration should be given to official guidance on the appropriate use of antiviral agents.
What is the active substance in Livtencity?
Livtencity contains maribavir.
Who makes Livtencity?
The EU marketing authorisation holder is Takeda Pharmaceuticals International AG Ireland Branch.
Is Livtencity an orphan medicine?
Yes. Livtencity is designated an orphan medicine in the EU, for a rare disease (Cytomegalovirus Infections).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU